Pharma Business Week
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Pharma Business Week
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Allergy & Immunology
FDA OKs reformulated Clarinex orally disintegrating prescription antihistamine
August 15th, 2005
Schering-Plough Corp. (SGP) announced that the U.S. Food and Drug Administration (FDA) has approved reformulated Clarinex (desloratadine 2.5 mg and 5 mg) Reditabs tablets for the treatment of allergy symptoms caused by both perennial indoor and seasonal outdoor allergens and chronic idiopathic urticaria, or hives of unknown cause, in adults and children 6 years of age and older. The tablet disintegrates orally, is taken once-daily for 24-hour relief, and now comes in a new "tutti frutti" flavor. This new formulation will be available in both a 2.5 mg and a 5 mg dose, and will be in pharmacies nationwide in September 2005. The...
Source: Pharma Business Week (2005-08-15)
|
